Msi-H/DMMR gastroesophageal-junction cancer
Clinical trials for Msi-H/DMMR gastroesophageal-junction cancer explained in plain language.
Never miss a new study
Get alerted when new Msi-H/DMMR gastroesophageal-junction cancer trials appear
Sign up with your email to follow new studies for Msi-H/DMMR gastroesophageal-junction cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can immunotherapy wipe out stomach cancer before surgery?
Cure PausedThis trial tests whether giving immunotherapy drugs before surgery can completely eliminate tumors in patients with a specific type of stomach or gastro-esophageal junction cancer that has a high number of genetic mutations. Participants will receive either one drug (zimberelimab…
Matched conditions: MSI-H/DMMR GASTROESOPHAGEAL-JUNCTION CANCER
Phase 2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Cure
Last updated Aug 23, 2026 00:00 UTC
-
New antibody combo takes on Hard-to-Treat stomach cancers
Disease control OngoingThis study tests a new antibody drug, S095029, combined with the immunotherapy pembrolizumab in people with advanced stomach or gastro-esophageal junction cancer that has a specific genetic feature (MSI-H/dMMR). The trial aims to see if the combination is safe and can shrink tumo…
Matched conditions: MSI-H/DMMR GASTROESOPHAGEAL-JUNCTION CANCER
Phase 1/2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC